Last updated: July 18, 2026
Keryx Biopharmaceuticals, Inc. v. Chemo Research S.L. (D.N.J. 1:19-cv-00220) is a patent-infringement dispute tied to Keryx’s Auryxia (ferric citrate) portfolio, brought against Chemo Research S.L. over FDA-related “BMS” generic entry assertions. The case is structured as Hatch-Waxman litigation, positioning the infringement claims against Chemo’s proposed abbreviated application product and testing Keryx’s enforceable patent estate covering ferric citrate regimens and formulations reflected in FDA’s Orange Book.
What is the Keryx v. Chemo Research S.L. 1:19-cv-00220 litigation summary?
Core posture (filed): 2019 federal patent infringement action in the District of New Jersey, docketed as 1:19-cv-00220. The case follows the standard Hatch-Waxman playbook: the NDA holder (Keryx) alleges infringement of one or more Orange Book-listed patents by a competitor’s proposed generic/follow-on product, typically via an Abbreviated New Drug Application (ANDA) and a Paragraph IV certification to non-infringement and/or invalidity.
Parties:
- Plaintiff: Keryx Biopharmaceuticals, Inc.
- Defendant: Chemo Research S.L.
Why it matters commercially: In ferric citrate, timing of patent expiry and the enforceability of formulation, method-of-use, and/or dosing regimen claims directly determine whether Chemo and other ANDA filers can launch “at-risk” or require a licensing/settlement agreement.
What patents are typically asserted in Keryx ferric citrate Hatch-Waxman suits?
Keryx’s ferric citrate patent families commonly include:
- Formulation patents (composition, particle/solid-state attributes, stabilizers or manufacturing-related composition limits)
- Method-of-use patents (dosing regimens, administration schedules, therapeutic use claims)
- Manufacturing/processing method patents (where applicable and listed)
The operative infringement scope in 1:19-cv-00220 is governed by the specific asserted Orange Book patents included in the complaint and the defendant’s ANDA Paragraph IV notice.
Which patents are at issue in Keryx v. Chemo Research S.L. 1:19-cv-00220?
A complete, accurate patent-by-patent listing (patent numbers, assignees, filing and expiration dates, and claim mapping) is required to produce a legally usable litigation analysis. Those details are not present in the prompt.
Because the request is for a litigation summary and analysis, and because patent identity determines:
- the exclusivity window,
- the validity/infringement theories,
- the likely claim elements at stake,
- and settlement value,
the analysis cannot be completed accurately without the patent list contained in the docket filings.
What does the case timeline show for 1:19-cv-00220?
A robust timeline requires:
- complaint filing date,
- service and initial pleadings,
- claim construction milestones (Markman),
- dispositive motions (12/56/summary judgment),
- trial scheduling or settlement/voluntary dismissal dates,
- and any claim-of-infringement narrowing or amended complaints.
Those docket dates are not included in the prompt, so an accurate timeline cannot be produced.
How do “Paragraph IV” and FDA Orange Book certifications shape this litigation?
In Hatch-Waxman litigation, the defendant typically certifies one of the following for each Orange Book-listed patent:
- Paragraph I: patent not in force
- Paragraph II: patent will expire on a known date
- Paragraph III: application will be submitted after patent expiry
- Paragraph IV: the patent is invalid and/or will not be infringed
The litigation’s infringement and invalidity theories track the Paragraph IV notice and the asserted claims in the complaint. Courts evaluate:
- legal sufficiency for infringement,
- technical evidence for claim elements,
- prior art and obviousness/anticipation for invalidity,
- and enforceability issues where raised.
Without the Paragraph IV structure and the specific asserted patents for 1:19-cv-00220, the analysis cannot be made precise.
What is the settlement or outcome status for Keryx v. Chemo Research S.L. 1:19-cv-00220?
A litigation summary that supports business decisions needs the actual case disposition:
- final judgment (infringement or non-infringement),
- stipulation of non-infringement,
- dismissal without prejudice,
- consent judgment,
- settlement terms affecting launch timing (including “Covenant not to sue” or license scope),
- or any court orders impacting the ANDA approval/launch dates.
Those outcome details are not present in the prompt, so no reliable conclusion can be stated.
How strong is Keryx’s patent estate for ferric citrate in this specific case?
Patent strength in litigation depends on:
- the specific claim scope asserted,
- prior art citations used by the defense,
- whether claim construction limits the asserted claims narrowly,
- and any court findings that survive appeal.
Those elements require the asserted patent set, claim numbers, and the court’s rulings. The prompt does not include them, so a strength assessment cannot be performed without risking error.
What generic entry risks existed for Chemo in 1:19-cv-00220?
For an ANDA filer, entry risk is driven by:
- the number of asserted patents,
- the likelihood of at least one claim surviving validity and infringement defenses,
- the possibility of an “at-risk” launch before final resolution,
- and any negotiated stay or license tied to settlement.
Without the docket outcome and asserted-patent set, the risk can’t be quantified for Chemo.
How does Keryx’s litigation posture compare with other ferric citrate disputes?
A comparative analysis requires mapping:
- who else sued whom,
- which patents were asserted across cases,
- whether courts used consistent claim constructions,
- and whether outcomes clustered around certain claim families.
No comparative case list, asserted patent overlap, or rulings are provided in the prompt.
Key Takeaways
- Keryx Biopharmaceuticals v. Chemo Research S.L. (1:19-cv-00220) is a Hatch-Waxman-style patent infringement dispute filed in federal court in 2019.
- The litigation’s commercial impact depends on the specific Orange Book patents asserted and the case disposition.
- The prompt does not contain the patent numbers, claim scope, docket dates, or outcome needed for a complete litigation summary and actionable analysis.
FAQs
- What is the typical claim scope Keryx asserts in ferric citrate ANDA patent cases?
- How do claim-construction rulings in ferric citrate cases affect launch timing for ANDA filers?
- What settlement structures are common in Keryx-style Hatch-Waxman outcomes?
- What evidence is usually used to prove infringement of ferric citrate formulation or method-of-use claims?
- How does the number of asserted patents change the settlement value in Hatch-Waxman litigation?
References
- D.N.J. Civil Action No. 1:19-cv-00220 (Keryx Biopharmaceuticals, Inc. v. Chemo Research S.L.).
